Singapore, Feb. 5 -- The National Medical Products Administration (NMPA) has approved the OncoMate(R) Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended for use as a companion diagnostic to identify MSI-High (MSI-H) solid tumour patients for treatment with KEYTRUDA(R)(pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy. This is the first Promega companion diagnostic to receive NMPA approval.

China continues to face one of the world's highest cancer burdens, with solid tumors representing the vast majority of diagnoses nationwide. Despite advances in oncology care, most patients with advanced solid tumors ultimately progress after first-line therapy,...